Active  name:	Vanzacaftor calcium dihydrate
Brand name:	ALYFTREK
Innovator name	VERTEX PHARMACEUTICALS INC
Approval Date:	Dec 20, 2024
Therapeutic activity:	Binds to the different sites on the CFTR protein and have an additive effect  in facilitating the cellular processing and trafficking of select mutant forms of CFTR (F508del-CFTR) to increase the amount of CFTR Protein delivered to the cell su
Route of adminstration	Tablet, oral
Structure
Chemical name	calcium bis((14S)-8-[3-(2-{dispiro[2.0.2⁴.1³]heptan-7-yl}ethoxy)pyrazol-1- yl]-12,12-dimethyl-2,2,4-trioxo-2λ⁶-thia-3,9,11,18,23-pentaazatetracyclo[17.3.1.1¹¹, ¹⁴.0⁵ , ¹⁰]tetracosa-1(23),5,7,9,19,21- hexaen-3-ide) dihydrate
CAS	2374124-49-7
Dosage	4 mg base eq (4.24 mg of  vanzacaftor calcium dehydrate)& 10 mg base eq (10.6 mg of  vanzacaftor calcium dehydrate)
Molecular weight& molecular formuale	654.82 g/mol & C32H38N7O4S.Ca0.5.H2O
OB patents	US7495103B2; US7645789 B2; US7776905B2; US 8623905
Polymorhic patent	US9487525 B2;
NCE	12/20/2029
Solubility data	Insoluble in water.
Hygroscopicity	Not hygroscopic
Drugbank	DB18373
Chemspider	115010436

Orange book Patent Data

Cystic fibrosis (CF) is a genetic condition caused by mutations in the CFTR gene, which controls ion and fluid transport across epithelial cells. Mutations cause consequences, the most severe of which is life-limiting lung illness.Traditional therapies aimed to manage symptoms, but improvements in understanding CF’s molecular foundation resulted in small-molecule CFTR modulators. Ivacaftor, a potentiator, is approved for gating mutations. Dual combinations, such as ivacaftor/lumacaftor and ivacaftor/tezacaftor, combined a potentiator and a class 1 corrector for F508del homozygous patients. Most CF patients now receive triple-combination CFTR modulators, such as ivacaftor/tezacaftor/elexacaftor with an additional class 2 corrector, which has transformed the disease’s outlook. Vanzacaftor/tezacaftor/deutivacaftor comes under class 2 corrector.